Revolution Medicines (NASDAQ:RVMD) Shares Down 5.9% – Should You Sell?

Revolution Medicines, Inc. (NASDAQ:RVMD) shares fell 5.9% during trading on Friday . The stock traded as low as $207.83 and last traded at $208.21. 594,307 shares were traded during trading, a decline of 80% from the average session volume of 3,008,394 shares. The stock had previously closed at $221.15.

Key Revolution Medicines News

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: The FDA approved RASONQUE (daraxonrasib) for previously treated metastatic pancreatic cancer, giving Revolution Medicines its first marketed product and a commercial foothold. The treatment is described as the first broad RAS-targeted medicine for this indication. FDA approval announcement
• Positive Sentiment: Analysts see substantial commercial potential: clinical data reportedly showed a meaningful survival benefit in pancreatic cancer, while estimates cited by The Motley Fool project up to $11.5 billion in peak sales. The expanded RASONQUE label could further increase the addressable market. The Motley Fool article
• Positive Sentiment: Several firms raised their targets following the approval. Guggenheim increased its target from $240 to $275 and assigned a Buy rating; HC Wainwright maintained Buy with a $280 target, while Wedbush and Truist also raised targets and retained positive ratings.
• Positive Sentiment: RBC reportedly expects a rapid RASONQUE launch, and Revolution’s decision to remain independent allows it to retain more potential long-term value from the product rather than selling to a larger pharmaceutical company. RBC launch analysis
• Neutral Sentiment: HC Wainwright forecasts continued losses but improving results in fiscal 2027, projecting quarterly EPS of negative $2.06, negative $1.70, negative $1.62 and negative $1.47, followed by a full-year loss of negative $6.86 per share versus the current-year consensus loss of negative $8.82.
• Negative Sentiment: RASONQUE’s reported list price of approximately $39,800 per month could create reimbursement, access and public-perception challenges, potentially slowing adoption despite the approval. RASONQUE pricing report
• Negative Sentiment: After rising more than fivefold over the past year, RVMD’s valuation reflects significant success. Investors may be taking profits or demanding evidence of commercial sales before assigning additional upside, particularly while the company remains unprofitable.

Analysts Set New Price Targets

RVMD has been the topic of several research reports. Piper Sandler increased their price target on shares of Revolution Medicines to $172.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Sanford C. Bernstein upped their target price on shares of Revolution Medicines from $151.00 to $179.00 and gave the stock a “market perform” rating in a research note on Friday, August 21st. Oppenheimer boosted their target price on Revolution Medicines from $230.00 to $260.00 and gave the stock an “outperform” rating in a research note on Thursday. Guggenheim upped their price target on Revolution Medicines from $240.00 to $275.00 and gave the stock a “buy” rating in a report on Friday. Finally, Truist Financial increased their price target on Revolution Medicines from $231.00 to $239.00 and gave the company a “buy” rating in a research report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $198.89.

Revolution Medicines Stock Down 6.5%

The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38. The company has a market cap of $44.32 billion, a PE ratio of -23.44 and a beta of 1.39. The business’s 50 day moving average is $192.43 and its 200-day moving average is $148.17.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same quarter in the prior year, the firm earned ($1.31) EPS. As a group, analysts predict that Revolution Medicines, Inc. will post -8.82 EPS for the current year.

Insider Activity

In related news, insider Stephen Michael Kelsey sold 4,175 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $156.12, for a total transaction of $651,801.00. Following the completion of the transaction, the insider owned 291,876 shares in the company, valued at approximately $45,567,681.12. The trade was a 1.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Margaret A. Horn sold 60,400 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $160.17, for a total value of $9,674,268.00. Following the completion of the transaction, the chief operating officer directly owned 158,222 shares in the company, valued at $25,342,417.74. This trade represents a 27.63% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 212,497 shares of company stock valued at $38,206,486. Insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Contravisory Investment Management Inc. purchased a new position in shares of Revolution Medicines in the 2nd quarter valued at about $32,000. Global Retirement Partners LLC lifted its stake in Revolution Medicines by 1,002.8% during the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock worth $32,000 after purchasing an additional 361 shares during the last quarter. Torren Management LLC purchased a new stake in Revolution Medicines during the fourth quarter worth approximately $33,000. Johnson Financial Group Inc. acquired a new position in Revolution Medicines in the second quarter valued at approximately $37,000. Finally, Arax Advisory Partners acquired a new position in Revolution Medicines in the fourth quarter valued at approximately $38,000. 94.34% of the stock is owned by institutional investors and hedge funds.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.